Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

Tze Sian Chan, Chung Chi Hsu, Vincent C. Pai, Wen Ying Liao, Shenq Shyang Huang, Kok Tong Tan, Chia Jui Yen, Shu Ching Hsu, Wei Yu Chen, Yan Shen Shan, Chi Rong Li, Michael T. Lee, Kuan Ying Jiang, Jui Mei Chu, Gi Shih Lien, Valerie M. Weaver, Kun-Chih Tsai

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment and metastasis has been attributed to expansion of stem-like tumor-initiating cells (TICs). Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the agents used, induces persistent STAT-1 and NF-κB activity in carcinoma-associated fibroblasts. This induction results in the expression and secretion of ELR motif-positive (ELR+) chemokines, which signal through CXCR-2 on carcinoma cells to trigger their phenotypic conversion into TICs and promote their invasive behaviors, leading to paradoxical tumor aggression after therapy. In contrast, the same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced stromal ELR+ chemokine paracrine signaling, thus enhancing treatment response and extending survival of mice carrying desmoplastic cancers. These experiments illustrate the importance of stroma in cancer therapy and how its impact on treatment resistance could be tempered by altering the dosing schedule of systemic chemotherapy.

Original languageEnglish
Pages (from-to)2967-2988
Number of pages22
JournalJournal of Experimental Medicine
Volume213
Issue number13
DOIs
Publication statusPublished - 2016

Fingerprint

Neoplastic Stem Cells
Drug Therapy
Neoplasms
Therapeutics
Chemokines
Paracrine Communication
Neoplasm Metastasis
Carcinoma
Survival
Maximum Tolerated Dose
Residual Neoplasm
Aggression
Heterografts
Appointments and Schedules
Fibroblasts
Recurrence
Growth

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. / Chan, Tze Sian; Hsu, Chung Chi; Pai, Vincent C.; Liao, Wen Ying; Huang, Shenq Shyang; Tan, Kok Tong; Yen, Chia Jui; Hsu, Shu Ching; Chen, Wei Yu; Shan, Yan Shen; Li, Chi Rong; Lee, Michael T.; Jiang, Kuan Ying; Chu, Jui Mei; Lien, Gi Shih; Weaver, Valerie M.; Tsai, Kun-Chih.

In: Journal of Experimental Medicine, Vol. 213, No. 13, 2016, p. 2967-2988.

Research output: Contribution to journalArticle

Chan, TS, Hsu, CC, Pai, VC, Liao, WY, Huang, SS, Tan, KT, Yen, CJ, Hsu, SC, Chen, WY, Shan, YS, Li, CR, Lee, MT, Jiang, KY, Chu, JM, Lien, GS, Weaver, VM & Tsai, K-C 2016, 'Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells', Journal of Experimental Medicine, vol. 213, no. 13, pp. 2967-2988. https://doi.org/10.1084/jem.20151665
Chan, Tze Sian ; Hsu, Chung Chi ; Pai, Vincent C. ; Liao, Wen Ying ; Huang, Shenq Shyang ; Tan, Kok Tong ; Yen, Chia Jui ; Hsu, Shu Ching ; Chen, Wei Yu ; Shan, Yan Shen ; Li, Chi Rong ; Lee, Michael T. ; Jiang, Kuan Ying ; Chu, Jui Mei ; Lien, Gi Shih ; Weaver, Valerie M. ; Tsai, Kun-Chih. / Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. In: Journal of Experimental Medicine. 2016 ; Vol. 213, No. 13. pp. 2967-2988.
@article{3b40d6eb50464c8bbed18afb6a38ed30,
title = "Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells",
abstract = "Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment and metastasis has been attributed to expansion of stem-like tumor-initiating cells (TICs). Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the agents used, induces persistent STAT-1 and NF-κB activity in carcinoma-associated fibroblasts. This induction results in the expression and secretion of ELR motif-positive (ELR+) chemokines, which signal through CXCR-2 on carcinoma cells to trigger their phenotypic conversion into TICs and promote their invasive behaviors, leading to paradoxical tumor aggression after therapy. In contrast, the same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced stromal ELR+ chemokine paracrine signaling, thus enhancing treatment response and extending survival of mice carrying desmoplastic cancers. These experiments illustrate the importance of stroma in cancer therapy and how its impact on treatment resistance could be tempered by altering the dosing schedule of systemic chemotherapy.",
author = "Chan, {Tze Sian} and Hsu, {Chung Chi} and Pai, {Vincent C.} and Liao, {Wen Ying} and Huang, {Shenq Shyang} and Tan, {Kok Tong} and Yen, {Chia Jui} and Hsu, {Shu Ching} and Chen, {Wei Yu} and Shan, {Yan Shen} and Li, {Chi Rong} and Lee, {Michael T.} and Jiang, {Kuan Ying} and Chu, {Jui Mei} and Lien, {Gi Shih} and Weaver, {Valerie M.} and Kun-Chih Tsai",
year = "2016",
doi = "10.1084/jem.20151665",
language = "English",
volume = "213",
pages = "2967--2988",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "13",

}

TY - JOUR

T1 - Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

AU - Chan, Tze Sian

AU - Hsu, Chung Chi

AU - Pai, Vincent C.

AU - Liao, Wen Ying

AU - Huang, Shenq Shyang

AU - Tan, Kok Tong

AU - Yen, Chia Jui

AU - Hsu, Shu Ching

AU - Chen, Wei Yu

AU - Shan, Yan Shen

AU - Li, Chi Rong

AU - Lee, Michael T.

AU - Jiang, Kuan Ying

AU - Chu, Jui Mei

AU - Lien, Gi Shih

AU - Weaver, Valerie M.

AU - Tsai, Kun-Chih

PY - 2016

Y1 - 2016

N2 - Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment and metastasis has been attributed to expansion of stem-like tumor-initiating cells (TICs). Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the agents used, induces persistent STAT-1 and NF-κB activity in carcinoma-associated fibroblasts. This induction results in the expression and secretion of ELR motif-positive (ELR+) chemokines, which signal through CXCR-2 on carcinoma cells to trigger their phenotypic conversion into TICs and promote their invasive behaviors, leading to paradoxical tumor aggression after therapy. In contrast, the same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced stromal ELR+ chemokine paracrine signaling, thus enhancing treatment response and extending survival of mice carrying desmoplastic cancers. These experiments illustrate the importance of stroma in cancer therapy and how its impact on treatment resistance could be tempered by altering the dosing schedule of systemic chemotherapy.

AB - Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment and metastasis has been attributed to expansion of stem-like tumor-initiating cells (TICs). Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the agents used, induces persistent STAT-1 and NF-κB activity in carcinoma-associated fibroblasts. This induction results in the expression and secretion of ELR motif-positive (ELR+) chemokines, which signal through CXCR-2 on carcinoma cells to trigger their phenotypic conversion into TICs and promote their invasive behaviors, leading to paradoxical tumor aggression after therapy. In contrast, the same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced stromal ELR+ chemokine paracrine signaling, thus enhancing treatment response and extending survival of mice carrying desmoplastic cancers. These experiments illustrate the importance of stroma in cancer therapy and how its impact on treatment resistance could be tempered by altering the dosing schedule of systemic chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85008433322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008433322&partnerID=8YFLogxK

U2 - 10.1084/jem.20151665

DO - 10.1084/jem.20151665

M3 - Article

VL - 213

SP - 2967

EP - 2988

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 13

ER -